CAR T Referral Process: Insights From Kansas
Al-Ola Abdallah, MD; Muhammad Umair Mushtaq, MD; Jeries Kort, MD; and Zahra Mahmoudjafari examine the evolving landscape of chimeric antigen receptor (CAR) T-cell therapy in earlier lines of treatment for relapsed/refractory multiple myeloma, exploring institutional challenges around patient selection, slot availability, referral processes, and decision-making frameworks while considering both clinical and practical factors that influence treatment sequencing and access.
EP. 1: Clinical Perspectives: Utilizing CAR-T Therapy in R/R MM
Panelists discuss how emerging data on chimeric antigen receptor T-cell therapies ciltacabtagene autoleucel and idecabtagene vicleucel for earlier treatment lines in relapsed/refractory multiple myeloma influence institutional decision-making factors for their implementation.
Panelists discuss how institutional challenges around chimeric antigen receptor T-cell therapy slot availability and waiting list management influence treatment sequencing decisions and affect subsequent therapy choices in earlier treatment lines for multiple myeloma.
Panelists discuss how patient selection criteria for second-line chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma encompass both clinical eligibility guidelines and practical considerations, including geographical and financial factors.
EP. 4: University of Kansas Medical Center Insights: CAR T Referral Process
Panelists discuss how the chimeric antigen receptor T-cell referral pathway progresses from initial community physician contact through patient evaluation and final selection, highlighting the key steps and considerations in the institutional workflow process.
EP. 5: Reviewing CAR T Mechanism & Treatment Process
Panelists discuss how CAR T-cell therapy, a groundbreaking immunotherapy treatment, works by extracting a patient’s T cells, genetically modifying them to target cancer cells, and reinfusing them back into the patient’s body through a process that involves close monitoring and specialized care
EP. 6: Approaches to Bridging Therapy During the CAR T Manufacturing Process
Panelists discuss how bridging therapy during the CAR T manufacturing waiting period requires careful patient-specific decisions about whether to use chemotherapy, targeted agents, or observation alone, based on disease aggressiveness, patient condition, and expected manufacturing timeframes.
